Inhibition of PDZ domain-mediated interactions

Drug Discovery Today: Technologies

Volumn 10, Issue 4, 2013, Pages

  Grillo Bosch, Dolors ^a,b   Choquet, Daniel ^a,b   Sainlos, Matthieu ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b University of Bordeaux   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; PDZ PROTEIN; PEPTIDOMIMETIC AGENT; PROTEIN INHIBITOR; SYNTROPHIN;

AMINO ACID SEQUENCE; ARTICLE; BIOENGINEERING; CEREBROVASCULAR ACCIDENT; CHEMICAL MODIFICATION; CYTOTOXICITY; DRUG STRUCTURE; DRUG TARGETING; NONHUMAN; PDZ DOMAIN; PHAGE DISPLAY; PROTEIN PROTEIN INTERACTION;

ANIMALS; DRUG DISCOVERY; HUMANS; LIGANDS; PDZ DOMAINS; PEPTIDES; PROTEIN INTERACTION MAPPING;

EID: 84886242382     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2012.10.003     Document Type: Review

References (50)

1. K. Luck The emerging contribution of sequence context to the specificity of protein interactions mediated by PDZ domains FEBS Lett. 586 2012 2648 2661
2. M. Sheng, and C. Sala PDZ domains and the organization of supramolecular complexes Annu. Rev. Neurosci. 24 2001 1 29
3. C. Nourry PDZ domain proteins: plug and play! Sci. STKE 2003 RE7 10.1126/stke.2003.1179.re1127
4. R. Tonikian A specificity map for the PDZ domain family PLoS Biol. 6 2008 e239
5. I.A. Lim Disruption of the NMDA receptor-PSD-95 interaction in hippocampal neurons with no obvious physiological short-term effect Neuropharmacology 45 2003 738 754
6. R.T. Javier, and A.P. Rice Emerging theme: cellular PDZ proteins as common targets of pathogenic viruses J. Virol. 85 2011 11544 11556
7. S.K. Florio Disruption of nNOS-PSD95 protein-protein interaction inhibits acute thermal hyperalgesia and chronic mechanical allodynia in rodents Br. J. Pharmacol. 158 2009 494 506
8. D. Grandy Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled J. Biol. Chem. 284 2009 16256 16263
9. T.S. Thorsen Identification of a small-molecule inhibitor of the PICK1 PDZ domain that inhibits hippocampal LTP and LTD Proc. Natl. Acad. Sci. U. S. A. 107 2010 413 418
10. A. Bach Structure-activity relationships of a small-molecule inhibitor of the PDZ domain of PICK1 Org. Biomol. Chem. 8 2010 4281 4288
11. W. Zhang Functional regulation of cystic fibrosis transmembrane conductance regulator-containing macromolecular complexes: a small-molecule inhibitor approach Biochem. J. 435 2011 451 462
12. L. Zhou Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95 Nat. Med. 16 2010 1439 1443
13. N. Fujii A selective irreversible inhibitor targeting a PDZ protein interaction domain J. Am. Chem. Soc. 125 2003 12074 12075
14. J. Saupe Discovery, structure-activity relationship studies, and crystal structure of nonpeptide inhibitors bound to the Shank3 PDZ domain ChemMedChem 6 2011 1411 1422
15. H-J. Lee Sulindac inhibits canonical wnt signaling by blocking the PDZ domain of the protein dishevelled Angew. Chem. Int. Ed. Engl. 48 2009 6448 6452
16. J. Xia Cerebellar long-term depression requires PKC-regulated interactions between GluR2/3 and PDZ domain-containing proteins Neuron 28 2000 499 510
17. W.W. Wang Transduced PDZ1 domain of PSD-95 decreases Src phosphorylation and increases nNOS (Ser847) phosphorylation contributing to neuroprotection after cerebral ischemia Brain Res. 1328 2010 162 170
18. S.Q. Hu Overexpression of PDZ1 domain prevents apoptosis of rat hippocampal neurons induced by kainic acid Neurosci. Lett. 460 2009 133 137
19. S.A. Fenske Overexpression of the PDZ1 domain of PDZK1 blocks the activity of hepatic scavenger receptor, class B, type I by altering its abundance and cellular localization J. Biol. Chem. 283 2008 22097 22104
20. F. Tao Cell-permeable peptide Tat-PSD-95 PDZ2 inhibits chronic inflammatory pain behaviors in mice Mol. Ther. 16 2008 1776 1782
21. M. Ferrer Directed evolution of PDZ variants to generate high-affinity detection reagents Protein Eng. Des. Sel. 18 2005 165 173
22. M. Aarts Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions Science 298 2002 846 850
23. D.J. Cook Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain Nature 483 2012 213 217
24. H. Hirbec Rapid and differential regulation of AMPA and kainate receptors at hippocampal mossy fibre synapses by PICK1 and GRIP Neuron 37 2003 625 638
25. P. Li AMPA receptor-PDZ interactions in facilitation of spinal sensory synapses Nat. Neurosci. 2 1999 972 977
26. M.H. Muders Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth Clin. Cancer Res. 15 2009 4095 4103
27. F. Bertaso PICK1 uncoupling from mGluR7a causes absence-like seizures Nat. Neurosci. 11 2008 940 948
28. K.E. Roberts Computational design of a PDZ domain peptide inhibitor that rescues CFTR activity PLoS Comput. Biol. 8 2012 e1002477
29. L. Vouilleme Engineering peptide inhibitors to overcome PDZ binding promiscuity Angew. Chem. Int. Ed. Engl. 49 2010 9912 9916
30. P.R. Cushing A stabilizing influence: CAL PDZ inhibition extends the half-life of ΔF508-CFTR Angew. Chem. Int. Ed. Engl. 49 2010 9907 9911
31. N. Babault Peptides targeting the PDZ domain of PTPN4 are efficient inducers of glioblastoma cell death Structure 19 2011 1518 1524
32. Y. Zhang Inhibition of Wnt signaling by dishevelled PDZ peptides Nat. Chem. Biol. 5 2009 217 219
33. M.R. Emond AMPA receptor subunits define properties of state-dependent synaptic plasticity J. Physiol. 588 Pt 11 2010 1929 1946
34. K.A. Novak Investigation of the PDZ domain ligand binding site using chemically modified peptides Bioorg. Med. Chem. Lett. 12 2002 2471 2474
35. D.G. Udugamasooriya A chemical library approach to organic-modified peptide ligands for PDZ domain proteins: a synthetic, thermodynamic and structural investigation Chembiochem 9 2008 1587 1589
36. C.R. Patra Chemically modified peptides targeting the PDZ domain of GIPC as a therapeutic approach for cancer ACS Chem. Biol. 7 2012 770 779
37. A. Bach Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-d-aspartate receptor interaction J. Med. Chem. 51 2008 6450 6459
38. T. Li Thermodynamic profiling of conformationally constrained cyclic ligands for the PDZ domain Bioorg. Med. Chem. Lett. 14 2004 1385 1388
39. A. Piserchio Targeting specific PDZ domains of PSD-95; structural basis for enhanced affinity and enzymatic stability of a cyclic peptide Chem. Biol. 11 2004 469 473
40. B.W. LeBlanc A cyclic peptide targeted against PSD-95 blocks central sensitization and attenuates thermal hyperalgesia Neuroscience 167 2010 490 500
41. M.C. Hammond β strand peptidomimetics as potent PDZ domain ligands Chem. Biol. 13 2006 1247 1251
42. S. Seedorff Design, synthesis, structure and binding properties of PDZ binding, cyclic β-finger peptides Biochem. Biophys. Res. Commun. 395 2010 535 539
43. S.H. Gee Cyclic peptides as non-carboxyl-terminal ligands of syntrophin PDZ domains J. Biol. Chem. 273 1998 21980 21987
44. A. Bach Cell-permeable and plasma-stable peptidomimetic inhibitors of the postsynaptic density-95/N-methyl-d-aspartate receptor interaction J. Med. Chem. 54 2011 1333 1346
45. M. Sainlos A general screening strategy for peptide-based fluorogenic ligands: probes for dynamic studies of PDZ domain-mediated interactions J. Am. Chem. Soc. 131 2009 6680 6682
46. C. Hoppmann Photocontrol of contracting muscle fibers Angew. Chem. Int. Ed. Engl. 50 2011 7699 7702
47. L. Bard Dynamic and specific interaction between synaptic NR2-NMDA receptor and PDZ proteins Proc. Natl. Acad. Sci. U. S. A. 107 2010 19561 19566
48. M. Sainlos Biomimetic divalent ligands for the acute disruption of synaptic AMPAR stabilization Nat. Chem. Biol. 7 2011 81 91
49. A. Bach A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage Proc. Natl. Acad. Sci. U. S. A. 109 2012 3317 3322
50. C.K. Wang Extensions of PDZ domains as important structural and functional elements Protein Cell 1 2010 737 751